壽仙谷(603896.SH):康壽製藥的六味地黃丸、補中益氣丸、金鎖固精丸獲得再註冊批准通知書
格隆匯1月16日丨壽仙谷(603896.SH)公佈,近日,浙江壽仙谷醫藥股份有限公司全資子公司金華市康壽製藥有限公司(簡稱“康壽製藥”)收到浙江省藥品監督管理局核准簽發的《藥品再註冊批准通知書》。六味地黃丸、補中益氣丸、金鎖固精丸獲批再註冊。
六味地黃丸具有滋陰補腎的功效。用於腎陰虧損,頭暈耳鳴,腰膝痠軟,骨蒸潮熱,盜汗遺精。補中益氣丸具有補中益氣,昇陽舉陷的功效。用於脾胃虛弱、中氣下陷所致的體倦乏力、食少腹脹、便溏久瀉、肛門下墜。金鎖固精丸具有固腎澀精的功效,用於腎虛不固,遺精滑泄,神疲乏力,四肢痠軟,腰疼耳鳴。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.